Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Schauer NJ"'
Autor:
Chan WC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Magin RS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Girardi NM; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA., Hu W; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Tarazona Guzman MI; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Starnbach CA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Felix A; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Adelmant G; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA., Varca AC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Hu B; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Bratt AS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., DaSilva E; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Schauer NJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jaen Maisonet I; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Dolen EK; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ayala AX; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Marto JA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. jarrod_marto@dfci.harvard.edu.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. jarrod_marto@dfci.harvard.edu., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2023 Feb 08; Vol. 14 (1), pp. 686. Date of Electronic Publication: 2023 Feb 08.
Autor:
Yang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Weisberg EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Magin RS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Chan WC; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Hu B; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Schauer NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Zhang S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Lamberto I; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Doherty L; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Cabal-Hierro L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Winer E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. james_griffin@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. james_griffin@dfci.harvard.edu., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publikováno v:
Leukemia [Leukemia] 2022 Jan; Vol. 36 (1), pp. 210-220. Date of Electronic Publication: 2021 Jul 29.
Autor:
Bushman JW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Schauer NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Hu W; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Varca AC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: eric_fischer@dfci.harvard.edu.
Publikováno v:
Cell chemical biology [Cell Chem Biol] 2021 Jan 21; Vol. 28 (1), pp. 78-87.e3. Date of Electronic Publication: 2020 Oct 01.
Autor:
Schauer NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Magin RS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Doherty LM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2020 Mar 26; Vol. 63 (6), pp. 2731-2750. Date of Electronic Publication: 2019 Nov 20.
Autor:
Schauer NJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Magin RS; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Doherty LM; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Chan WC; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Hu W; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Roberts RM; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Iacob RE; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA., Stolte B; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.; Dr. von Hauner Children's Hospital, Department of Pediatrics, University Hospital, LMU Munich, Munich, Germany.; The Broad Institute of MIT and Harvard University, Cambridge, MA, USA., Giacomelli AO; The Broad Institute of MIT and Harvard University, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Perera S; Harvard College, Cambridge, MA, USA., McKay K; Department of Chemistry, University of Vermont, Burlington, VT, USA., Boswell SA; Department of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Weisberg EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ray A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA., Chauhan D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA., Dhe-Paganon S; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li J; Department of Chemistry, University of Vermont, Burlington, VT, USA., Hahn WC; The Broad Institute of MIT and Harvard University, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Sorger PK; Department of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Engen JR; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.; The Broad Institute of MIT and Harvard University, Cambridge, MA, USA., Marto JA; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Buhrlage SJ; Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publikováno v:
Scientific reports [Sci Rep] 2020 Mar 24; Vol. 10 (1), pp. 5324. Date of Electronic Publication: 2020 Mar 24.
Autor:
Harris IS; Ludwig Cancer Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA., Endress JE; Ludwig Cancer Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA., Coloff JL; Ludwig Cancer Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA., Selfors LM; Harvard Medical School, Boston, MA 02115, USA., McBrayer SK; Dana-Farber Cancer Institute, Boston, MA 02115, USA., Rosenbluth JM; Ludwig Cancer Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA., Takahashi N; Ludwig Cancer Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA., Dhakal S; Harvard Medical School, Boston, MA 02115, USA., Koduri V; Dana-Farber Cancer Institute, Boston, MA 02115, USA., Oser MG; Dana-Farber Cancer Institute, Boston, MA 02115, USA., Schauer NJ; Dana-Farber Cancer Institute, Boston, MA 02115, USA., Doherty LM; Dana-Farber Cancer Institute, Boston, MA 02115, USA., Hong AL; Dana-Farber Cancer Institute, Boston, MA 02115, USA; Boston Children's Hospital, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, MA 02142, USA., Kang YP; Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Younger ST; Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, MA 02142, USA., Doench JG; Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, MA 02142, USA., Hahn WC; Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, MA 02142, USA; Brigham and Women's Hospital, Boston, MA 02115, USA., Buhrlage SJ; Harvard Medical School, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA., DeNicola GM; Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Kaelin WG Jr; Dana-Farber Cancer Institute, Boston, MA 02115, USA., Brugge JS; Ludwig Cancer Center, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: joan_brugge@hms.harvard.edu.
Publikováno v:
Cell metabolism [Cell Metab] 2019 May 07; Vol. 29 (5), pp. 1166-1181.e6. Date of Electronic Publication: 2019 Feb 21.
Autor:
Stolte B; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.; Dr. von Hauner Children's Hospital, Department of Pediatrics, University Hospital, LMU Munich, Munich, Germany.; The Broad Institute of MIT and Harvard, Cambridge, MA., Iniguez AB; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.; The Broad Institute of MIT and Harvard, Cambridge, MA., Dharia NV; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.; The Broad Institute of MIT and Harvard, Cambridge, MA., Robichaud AL; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA., Conway AS; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA., Morgan AM; Department of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA., Alexe G; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA.; The Broad Institute of MIT and Harvard, Cambridge, MA.; Bioinformatics Graduate Program, Boston University, Boston, MA., Schauer NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Bird GH; Department of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA., Tsherniak A; The Broad Institute of MIT and Harvard, Cambridge, MA., Vazquez F; The Broad Institute of MIT and Harvard, Cambridge, MA., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Walensky LD; Department of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA loren_walensky@dfci.harvard.edu., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA kimberly_stegmaier@dfci.harvard.edu.; The Broad Institute of MIT and Harvard, Cambridge, MA.
Publikováno v:
The Journal of experimental medicine [J Exp Med] 2018 Aug 06; Vol. 215 (8), pp. 2137-2155. Date of Electronic Publication: 2018 Jul 25.
Autor:
Lamberto I; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Schauer NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Iacob RE; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA., Hu W; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Das D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Mikhailova T; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Weisberg EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Engen JR; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Chauhan D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: dhepag@crystal.harvard.edu., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: saraj_buhrlage@dfci.harvard.edu.
Publikováno v:
Cell chemical biology [Cell Chem Biol] 2017 Dec 21; Vol. 24 (12), pp. 1490-1500.e11. Date of Electronic Publication: 2017 Oct 19.
Autor:
Weisberg EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Schauer NJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Yang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Lamberto I; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Doherty L; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Bhatt S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Nonami A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Wright R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Tiv H; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Gokhale PC; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Ritorto MS; MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, UK., De Cesare V; MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, UK., Trost M; MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, UK., Christodoulou A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Christie A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Adamia S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Chauhan D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v:
Nature chemical biology [Nat Chem Biol] 2017 Dec; Vol. 13 (12), pp. 1207-1215. Date of Electronic Publication: 2017 Oct 02.